Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06617897

Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

A Phase 3, Single-center, Randomized, Controlled Clinical Study to Investigate the Efficacy of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

Sponsor: CSL Behring

Conditions Acquired Fibrinogen Deficiency

Interventions CSL511 Fibrinogen concentrate (human) Cryoprecipitate

Updated 5 times since 2024 Last updated: Mar 9, 2026 Started: Oct 1, 2024 Primary completion: Sep 1, 2027 Completion: Oct 29, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06617897, this PHASE3 trial focuses on Acquired Fibrinogen Deficiency and remains actively recruiting participants. Sponsored by CSL Behring, it has been updated 5 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE3
Jun 2025 — Mar 2026 [monthly]

Recruiting PHASE3
Feb 2025 — Jun 2025 [monthly]

Recruiting PHASE3
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Oct 2024 — Jan 2025 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSL Behring

Data source: CSL Behring

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Basingstoke, United Kingdom